Sulfonamide inhibition of bone resorption: lack of a hypophosphatemia

Calcitonin and acetazolamide inhibit bone resorption in the ureter-ligated rat. Calcitonin treatment results in an ensuing hypocalcemia and hypophosphatemia. Although acetazolamide treatment results in a hypocalcemic response similar to that seen with calcitonin, plasma phosphate concentrations incr...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pharmacology and experimental therapeutics Vol. 213; no. 3; p. 441
Main Authors L C Waite, W M Pierce, Jr, M D Lineberry
Format Journal Article
LanguageEnglish
Published United States American Society for Pharmacology and Experimental Therapeutics 01.06.1980
Subjects
Acetazolamide - pharmacology
Acidosis - metabolism
Animals
Bone Resorption - drug effects
Calcitonin - pharmacology
Carbon Dioxide - blood
Female
Hypocalcemia - chemically induced
Ligation
Phosphates - blood
Rats
Sulfonamides - pharmacology
Ureter - physiology
Online AccessGet full text

Cover

More Information
Summary:Calcitonin and acetazolamide inhibit bone resorption in the ureter-ligated rat. Calcitonin treatment results in an ensuing hypocalcemia and hypophosphatemia. Although acetazolamide treatment results in a hypocalcemic response similar to that seen with calcitonin, plasma phosphate concentrations increase or remain unchanged after drug treatment. Data are presented indicating that acetazolamide exhibits two effects that influence blood phosphate. Drug treatment of ureter-ligated rats results in an inhibition of bone resorption which tends to lower blood phosphate concentrations. However, this effect is masked by a drug-induced hypercapnia which results in an increase in plasma phosphate concentrations. Elevation of blood pCO2 also attenuates the hypophosphatemic response to calcitonin.
ISSN:0022-3565
1521-0103